Law360, San Diego (June 17, 2011, 8:10 PM ET) -- When Switzerland-based Actelion Ltd. — accused of interfering with Asahi Kasei Pharma Corp.’s licensing agreement to develop cardiovascular drug Fasudil — began attacking the drug at trial by calling it ineffective and even dangerous, Asahi’s attorneys from Morgan Lewis & Bockius LLP had a choice: they could either dodge the arguments or face them head on.
The Morgan Lewis team refused to run from the challenges against Fasudil, which was already approved in Japan and China for a certain type of stroke, but had not yet...
How They Won It: Morgan Lewis Snags $577M Verdict For Asahi
To view the full article, take a free trial now.
